

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 26<sup>th</sup> June, 2020

To,  
**Bombay Stock Exchange Limited**  
**Department of Corporate Services**  
**25<sup>th</sup> Floor, P. J. Towers, Dalal Street,**  
**Mumbai-400 001**

Script ID: 506365

**SUBJECT: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31/03/2020, DECLARATION, FORM 'A' AND AUDITORS REPORT IN BOARD MEETING HELD ON 26<sup>TH</sup> JUNE, 2020**

Dear Sirs,

Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on Friday, 26<sup>th</sup> June, 2020 at 04:00 P.M. at Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai – 400 001 approved the following:

1. Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2020
2. Form 'A' for the year ended 31<sup>st</sup> March, 2020
3. Auditors Report on Standalone Financial Results for the year ended 31<sup>st</sup> March, 2020
4. Declaration regarding Audit Report with unmodified opinion

The Company will not be publishing these Financial Results in the newspaper under Regulation 47 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, in view of SEBI Circular dated 12<sup>th</sup> May, 2020 vide circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 and on account of the lock-down restrictions imposed by the Government of India.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

*Ashok Somani*

ASHOK SOMANI  
DIRECTOR  
(DIN - 03063364)



Place: Mumbai

# CHEMO PHARMA LABORATORIES LIMITED






Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	<b>CHEMO PHARMA LABORATORIES LIMITED</b>
2.	Annual Financial Statements for the year ended	31 <sup>st</sup> March, 2020
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	 
	• Audit Committee Chairman – Balkishan Lohia	



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001






• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the Financial Year 2019-2020 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2019-2020, along with the Financial Results on 26<sup>th</sup> June, 2020. We hereby confirm that auditors have expressed an Un-modified Opinion in their Audit Reports on Standalone Financial Statements

1.	Name of the Company:	<b>CHEMO PHARMA LABORATORIES LIMITED</b>
2.	Annual Financial Statements for the year ended	31 <sup>st</sup> March, 2020
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	 
	• Audit Committee Chairman – Balkishan Lohia	





**AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To the Board of Directors of **CHEMO PHARMA LABORATORIES LIMITED**

We have audited the quarterly financial results of ChemoPharma Laboratories Limited for the quarter ended March 31, 2020 and the year to date results for the period April 1, 2019 to March 31, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2020 as well as the year to date results for the period from April 1, 2019 to March 31, 2020.

**For VMD & Co.**  
**Chartered Accountants**  
**FRN: 125002W**

**CA Amit Ganpule**  
**Partner**  
**MRN: 114222**  
**Place : Mumbai**  
**Date: June 26, 2020**  
**UDIN:**

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301  
 • Corporate Office :- Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001  
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31<sup>ST</sup> MARCH, 2020

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31 <sup>st</sup> March 2020	31 <sup>st</sup> Dec., 2019	31st March 2019	31 <sup>st</sup> March 2019	31 <sup>st</sup> March 2020
		Un-audited	Un-audited	Un-audited	Audited	Audited
I	Revenue from Operations	-	-	-	-	-
II	Other Income	2,859	1,499	4,266	8,225	9,967
III	<b>Total Revenue (I + II)</b>	<b>2,859</b>	<b>1,499</b>	<b>4,266</b>	<b>8,225</b>	<b>9,967</b>
IV	<b>Expenses</b>					
	(1) Cost Materials consumed	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	(4) Finance Costs	-	-	-	-	-
	(5) Employee Benefits Expenses	404	574	526	2,218	1,813
	(6) Depreciation and Amortisation Expenses	231	-	-	47	231
	(7) Administrative and Other Expenses	1,253	242	854	3,414	2,982
	i) Professional Charges	-	-	-	-	-
	ii) Share Registry Expenses	-	-	-	-	-
	iii) Annual Listing Fees	-	-	-	-	-
	iv) Postal Charges	-	-	-	-	-
	<b>Total Expenses</b>	<b>1,888</b>	<b>816</b>	<b>1,380</b>	<b>5,679</b>	<b>5,026</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>971</b>	<b>683</b>	<b>2,886</b>	<b>2,546</b>	<b>4,941</b>
VI	Exceptional Items	-	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>971</b>	<b>683</b>	<b>2,886</b>	<b>2,546</b>	<b>4,941</b>
VIII	Extra Ordinary Items	-	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>971</b>	<b>683</b>	<b>2,886</b>	<b>2,546</b>	<b>4,941</b>
X	Tax Expenses					
	(1) Current Tax	760	-	460	460	760
	(2) Tax Adjusted Previous Year	30	-	-	23	30
	(3) Deferred Tax	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	181	683	2,426	2,063	4,151
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>181</b>	<b>683</b>	<b>2,426</b>	<b>2,063</b>	<b>4,151</b>
XVI	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
XVII	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>181</b>	<b>683</b>	<b>2,426</b>	<b>2,063</b>	<b>4,151</b>
XVIII	<b>Earnings per Share :</b>					
	Basic (1)	<b>0.12</b>	<b>0.46</b>	<b>1.62</b>	<b>1.38</b>	<b>2.77</b>
	(2) Diluted					

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Standalone Audited Financial Results for the Quarter and Year Ended 31.03.2020 have been reviewed by the Audit Committee in their Meeting held on 26.06.2020 and approved by the Board of Directors of its Meeting held on 26.06.2020. The Audit Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai  
Date : 26th June, 2020



For Chemo Pharma Laboratories Limited

*Ashok Somani*

Ashok Somani  
Director  
DIN : 03063364

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2020

(Rupees in Thousands)

Sr. No.	PARTICULARS	As at 31.03.2020 Audited	As at 31.03.2019 Audited
1	<b>ASSETS</b>		
	<b>Non-Current Assets</b>		
	(A) Property, Plant and Equipement	747	30
	(B) Financial Assets		
	(i) Investment	237	369
	(ii) Loans	19,568	18,417
	<i>Total Non-current Assets</i>	20,552	18,816
	<b>Current Assets</b>		
	(i) Cash & Cash Equivalents	8,084	4,662
	(ii) Fixed Deposits	80,000	80,732
	(iii) Other Current Assets	1,021	732
	<i>Total Current Assets</i>	89,105	85,394
	<b>TOTAL ASSETS</b>	109,657	104,210
2	<b>EQUITY AND LIABILITIES</b>		
	<b>EQUITY</b>		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity	92,447	88,296
	<i>Total Equity</i>	107,447	103,296
	<b>Liabilities</b>		
	<b>Non- Current Liabilities</b>	-	-
	<b>Current Liabilities</b>		
	(i) Borrowings	-	-
	(ii) Other Current Liabilities	1,450	1,259
	(iii) Provisions	760	(343)
	<i>Total Current Liabilities</i>	2,210	914
	<b>TOTAL EQUITY AND LIABILITIES</b>	109,657	104,210

By Order of the Board  
For Chemo Pharma Laboratories Limited

*Ashok Somani*

ASHOK SOMANI  
DIRECTOR  
DIN : 03063364

Place : Mumbai  
Date : 26th June, 2020



# CHEMO PHARMA LABORATORIES LIMITED


Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301  
• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001  
• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & YEAR ENDED 31<sup>ST</sup> MARCH, 2020

(Rs. in Thousands)

PARTICULARS	STANDALONE	
	AUDITED QUARTER ENDED 31.03.2020	AUDITED YEAR ENDED 31.03.2020
<b>Reconciliation of Profit After Tax as reported earlier:</b>		
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>181</b>	<b>4,151</b>
<b>Benefit / (Charge):</b>	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>181</b>	<b>4,151</b>

For Chemo Pharma Laboratories Ltd.



Ashok Somani  
Director  
DIN : 03063364

Mumbai  
Date: 26th June, 2020

